Results
|
|
1.
|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). MedStar authors:
Year: 2012
Citation: - The International Journal of Cardiovascular Imaging. 28(3):455-65, 2012 Mar.
Institution: - MedStar Health Research Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - APPROACH study group, Brugaletta S, Garcia-Garcia HM, Garg S, Huang C, Kolatkar NS, Kravitz BG, Miller DM, Morocutti G, Nesto RW, Ratner RE, Serruys PW
|
|
|
2.
|
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. MedStar authors:
Year: 2016
Citation: - Journal of Clinical Endocrinology & Metabolism. 101(5):2056-62, 2016 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
|
3.
|
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. MedStar authors:
Year: 2016
Citation: - Journal of Clinical Endocrinology & Metabolism. 101(4):1754-61, 2016 Apr
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Aroda VR, Bray GA, Crandall JP, Diabetes Prevention Program Research Group, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Schade DS, Temprosa MG, White NH
|
|
|
4.
|
|
|
|
5.
|
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
Year: 2016
Citation: - Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
|
|
|
6.
|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
Year: 2017
Citation: - The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
|
|
|
7.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
8.
|
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
Year: 2020
Citation: - Diabetes Care. 43(5):940-947, 2020 05.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
|
